Association between Paraoxonase 1 Allelic Frequency Distribution, Adjusted Odds Ratios, and the Risk of Cardiovascular Diseases in a Moroccan population.

ABSTRACT:

Aim : Paraoxonase 1 (PON1) an antioxidant enzyme associated with high density lipoprotein (HDL) is expressed in the Islet of Langerhans and may play a protective role against oxidative stress. This study investigated the relationship between the PON1 phenotype, allelic frequency distribution and the risk of cardiovascular disease complications.

Methods : Three hundred subjects aged between 40-80 years including healthy controls, diabetic patients, and chronic renal failure/hemodialysis patients, were enrolled and divided into three groups of 100 subjects each. Participants were further stratified by age into middle-aged 40-59 years, (n=147), and elderly subjects 60-79 years (n = 153).

Plasma malondialdehyde levels were measured by HPLC using thiobarbituric acid (TBA) derivatization with fluorescence detection. Vitamin E (α-tocopherol) concentration was determined by HPLC with electrochemical detection.

Results : PON 1 allelic frequencies in healthy, diabetic and hemodialysis subjects were as respectively : Q alleles 86.62%, 85.46% and 79.78%; R alleles 13.37%, 14.53% and 20.22%. In hemodialysis patients, the adjusted odds ratio (OR) comparing the QQ with the RR phenotypes was 1.97 [95 % (CI): 0.63-6.21]. In diabetic patients, the OR comparing the QQ with the QR phenotypes was 1.37 [95% CI: 0.62-3.04]. PON1 activity was significantly higher in QR+RR carriers than in QQ carriers among diabetic and hemodialysis patients ($p<0.001$ for both groups). The vitamin E/Total Cholesterol ratio was significantly reduced in diabetic QQ carriers ($p<0.05$) and hemodialysis QQ carriers ($p<0.05$) compared with healthy subjects.

Conclusion : These finding suggest an association between changes in PON1 phenotype distribution, allelic frequencies, and the development of cardiovascular complication in diabetic and hemodialysis patients.

Keywords : Adjusted odd ratio, Paraoxonase 1, HPLC, Hemodialysis, Diabetes, MDA, Vitamin E

Introduction

Diabetes and renal failure are increasingly prevalent health problems in developing countries, including Morocco and represent major risk factors for cardiovascular disease and myocardial infarction [1-5]. Paraoxonase 1 (PON1) is an antioxidant enzyme associated with HDL that hydrolyzes lipid peroxides in LDL and atherosclerotic lesions [6-7]. Three paraoxonase isoforms have been identified (PON1, PON2 and PON3), although only PON1 exhibits true paraoxonase activity. Oxidized LDL plays a central role in the cardiovascular complications associated with diabetes and hemodialysis [7]. Reduced PON1 activity in diabetic and hemodialysis patients may contribute to increased susceptibly to lipid peroxidation, partly due to hyperglycaemia and the dialysis process [5-12]. Therefore, elevated paraoxonase activity may provide protective cardiovascular effects in these populations [2,13]. One of the factor determinants of PON1 activity is the Q192R genetic polymorphism, which give rises to two isoforms: Q (low Paraoxonase activity) and R (high Paraoxonase activity) [8, 9]. The R allele has been associated with increased risk factor for cardiovascular disease and diabetic or hemodialysis patients carrying this allele may be at greater risk of cardiovascular complications [2, 7-9].

Previously, we determined the distribution of PON1 phenotypes in a Moroccan population [2]. The present study aimed to investigate the association between alterations in PON1 phenotype distribution and the risk of cardiovascular disease in healthy subjects, diabetic patients, and hemodialysis patients.

1-Materials and methods

1-1 Subjects

Three hundred subjects aged 40-80 years were enrolled in this study. Participants were recruited from the Biomedical center of the Pasteur Institute of Casablanca for routine medical evaluation. Diabetic patients (n = 100) were recruited from local clinical centers, whereas hemodialysis patients (n = 100) were recruited from hemodialysis centers in Casablanca. Participants were divided into three group according to health status: healthy control (n=100), diabetic patients (n = 100), hemodialysis patients (n = 100). Pregnant and breastfeeding women were excluded, and only one individual per family was included among diabetic and hemodialysis patients.

Healthy subjects were nonsmokers and nondrinkers with no clinically apparent cardiovascular disease, normal renal and liver function and no clinical or laboratory evidence of diabetes or inflammation (hs-CRP < 3; fasting blood glucose < 6.1 mmol/l). None were taking medication or oral antioxidant supplements.

Among diabetic patients, 75 % were hypertensive, 23 % had a family history of diabetes, and most were receiving statin therapy. The mean duration of was 4.33 ± 2.42 years, and diabetic nephropathy was present in 22% of patients. One subject had previously undergone surgery for disc herniation, and another had a solitary kidney. Cardiovascular disease was present in 40 % of diabetic patients, and three patients were treated with insulin.

Hemodialysis subjects received standard unfractionated heparin administered in fractional doses every hour during dialysis sessions. The delivered dialysis dose corresponded to a Kt/V is 1.2. Patients underwent hemodialysis for 4 hours, three times per week, using bicarbonate-based dialysate. Hemophane membranes were the most used membranes. Among the hemodialysis subjects, 55 % were hypertensive and 15 % were receiving statin therapy.

The mean duration of hemodialysis treatment was 53 months. One subject had previously undergone kidney transplantation, another had valvular heart disease, and one subject had a solitary kidney. The study protocol was accepted by the ethics committee of the Faculty of Medicine and Pharmacy of Casablanca, and all participants provided written informed consent prior to enrollment.

All subjects underwent a physical examination and completed a self-administered questionnaire. This questionnaire collected information on demographic characteristics, participants' health status, family history of diabetes, hypertension and cardiovascular diseases. It also included information regarding the duration of diabetes and hemodialysis treatment.

Body mass index (BMI) was calculated from weight and Height measurments. Blood pressure was measured twice on the right arm in supine position after 5-minutes rest period to determine hypertension according to the 1999 World Health Organisation criteria. Measurement were performed under quiet conditions and in the absence of emotional stress.

1-2 Blood and urine collection and lipid profile measurements

After an overnight fast, 80 mL of blood were collected into sodium heparin- or EDTA-containing tubes. Plasma was separated by centrifugation (3000 x g, for 10 min) and serum aliquots were stored at – 80 º C until analysis. Microalbuminuria was in two consecutive 24-h urine samples using a BN 100 nephelometer system (Dade Behring, Germany). Serum urea and creatinine levels were assessed before each dialysis session in hemodialysis patients. Serum total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and HbA1c were measured using automated enzymatic assays (Kodak, Ektachem USA System). Serum total cholesterol levels were determining by measuring absorbance at 550 nm.

1.3. Paraoxonase activity

PON1 activity was determined using paraoxon (O,O-diethyl-O-p-nitrophenylphosphate; Sigma) as the substrate by measuring the increase in absorbance at 412 nm resulting from the formation of 4-nitrophenol, as previously described [2]. Briefly, 50 µl of serum were added to 1 ml of Tris-HCl buffer (100 mmol/l, pH 8.0) containing 2 mmol/l CaCl2 and 5.5 mmol/l paraoxon [9, 11, 14, 15], and the reaction was monitored at 25 °C. Enzymatic activity was

calculated using a molar extinction coefficient 17,100 $M^{-1} cm^{-1}$. One unit of paraoxonase activity was defined as 1 nmol of 4-nitrophenol generated per minute under the assay conditions.

1.4. Arylesterase assay

Arylesterase activity was measured spectrophotometrically using phenylacetate as substrate in 20 mM Tris/HCl pH 8.0 [16]. The increase in absorbance was monitored at 270 nm, and enzyme activity was calculated using a molar extinction coefficient of 1310 $M^{-1} cm^{-1}$. One unit (U) corresponded to 1 μmol phenylacetate hydrolyzed per minute [6, 16].

1.5. Paraoxonase phenotype distribution

The PON1 Q192R polymorphism determines two isoforms: Q (low activity) and R (high activity) [8]. PON1 phenotype was determined using the dual substrate method based on the. ratio of salt-stimulated paraoxonase activity (1 mol/l NaCl) to arylesterase activity. Subjects were classified as QQ (ratio < 3.0), QR (ratio 3.0-7) and ratio>7.0, or RR phenotype (ratio > 7.0) [10, 11].

1.6. Statistical analysis

Statistical analysis were performed using SAS for windows version 6.11. Data are presented as mean +/- standard deviation of number cases. Comparisons between groups were performed using unpaired t-tests or ANOVA. Associations between variables were assessed using regression and Spearman correlation analyses. A two sided p value <0.05 was considered statistically significant.

2. Results

2.1. Baseline data

In the overall study population, MDA concentrations tended to be higher in carriers of the PON1 QR + RR phenotypes compared with carriers of the PON1 QQ phenotype ($p = 0.08$).

MDA concentrations were also higher in PON1 QR carriers than in PON1 RR carriers ($p = 0.08$). In contrast, subjects with the PON1 QR phenotype had significantly higher MDA concentrations than PON1 QQ carriers ($p < 0.05$) (Table 1).

Among PON1 QQ carriers, MDA levels were significantly higher in diabetic subjects ($p<0.05$) and hemodialysis subjects ($p<0.01$) compared with healthy subjects with the same phenotype. Similarly, diabetic and hemodialysis subjects carrying the PON1 QR phenotype had higher MDA levels than healthy PON1 QR carriers ($p<0.05$). Among PON1 RR carriers, MDA levels were increased in diabetic ($p = 0.32$) and hemodialysis subjects ($p = 0.33$) compared with healthy RR carriers, but these differences were not statistically significant.

Paraoxonase activity was significantly higher in subjects carrying the PON1 QR or RR phenotypes compared with PON1 QQ carriers ($p<0.001$). Indeed, arylesterase activity was significantly lower in carriers of the PON1 R allele (RR and QR) compared with carriers of the PON1 Q allele ($p<0.01$). Furthermore, arylesterase activity was significantly lower in PON1 RR carriers than in PON1 QR carriers ($p<0.01$) and in combined PON1 QR+RR carriers ($p<0.05$). Consistently, arylesterase activity was significantly higher in PON1 QQ carriers compared with combined PON1 QR + RR carriers ($p<0.001$) (Table 1).

Paraoxonase ($p<0.05$) and arylesterase ($p<0.05$) activities were significantly lower in the hemodialysis subjects across all three PON1 Q192R phenotypes compared with healthy subjects. In contrast, non-significant differences in paraoxonase activity were observed between healthy subjects and the diabetic patients for any of the three PON1 Q192R phenotypes, although a slight increase in serum PON1 activity was noted in diabetic patients. Paraoxonase ($p<0.05$) and Arylesterase ($p<0.01$) activities also differed significantly among the three PON1 Q192R phenotypes in both the diabetic and hemodialysis subjects. In healthy subjects, carriers of the PON1 QQ phenotype had significantly lower paraoxonase activity compared with QR + RR carriers ($p<0.001$). Similarly, paraoxonase activity was significantly higher in QR+RR carriers than in QQ carriers among diabetic ($p<0.001$) and hemodialysis patients ($p<0.001$).

Comparison of Vitamin E/Total cholesterol ratio in the overall study population according to the PON1 Q192R polymorphism showed a significant decrease in PON1 QR carriers when compared with PON1 QQ carriers ($p<0.05$). In contrast, the Vitamin E/total cholesterol ration was significantly lower in PON1 QQ carriers compared with combined PON1 QR + RR carriers ($p<0.05$). However, no significant difference in the vitamin E/total cholesterol ratio was observed between PON1 QQ and PON1 RR carriers ($p = 0.10$) (Table 1).

Vitamin E levels did not differ significantly among subjects according to the PON1 Q192R polymorphism; however, the Vitamin E/total cholesterol was significantly influenced by the PON1 phenotype (Table 1). Compared with healthy subjects carrying the PON1 QQ phenotype, the Vitamin E/total cholesterol ratio was significantly lower in diabetic ($p<0.05$) and hemodialysis subjects ($p<0.05$) carrying the same phenotype.

A significant decrease in the Vitamin E/total cholesterol ratio was observed in hemodialysis subjects carrying the PON1 QR phenotype compared with healthy QR carriers ($p<0.05$). Similarly, hemodialysis subjects carrying the PON1 RR phenotype had a significantly lower ratio Vitamin E/total cholesterol ratio than the healthy RR carriers ($p < 0.05$). Interestingly, the vitamin E/total cholesterol ratio was significantly decreased in hemodialysis subjects carrying the combined PON1 QR + RR phenotypes compared with healthy QR+RR carriers ($p<0.01$).

However, comparisons between PON1 QQ carriers and combined PON1 QR + RR carriers within healthy ($p = 0.14$), diabetic ($p = 0.32$), and hemodialysis subjects ($p = 0.10$) showed no significant differences in the Vitamin E/total cholesterol ratio.

Table 1 : Baseline characteristics (mean ± SD) according to PON1 Q/R in whole subjects (n=300)

Parameters	QQ (n=195)	QR (n=48)	QR+ RR (n=66)	RR (n=18)
Men (%)	58.46	46.93	46.97	47.05
Mean age, years	57.82±11.59	57.66±11.72	57.30±11.82	56.33±12.38
GJ (g/L)	1.50±1.00	1.52±0.60	1.53±0.64	1.57±0.83
TG, (mmol/L)	1.50±1.04	2.34±1.75***	2.33±1.74***	1.37±0.55
Serum MDA (μM)	7.43±3.83	8.76±4.61*	8.26±4.36	7.04±3.48
PON1 activity (U/mL)	38.68±47.95	110.45±119.40***	113.67±131.35***	118.09±147.87***
ARE activity (U/mL)	38.28±34.24	23.72±25.21**	19.47±23.02***¶	8.14±9.14**++
Vit. E (μM)	18.67±8.52	18.66±7.13	18.57±7.63	18.40±8.93
Vit.E/TC ratio (μmol/mmol)	4.66±2.42	3.78±1.83*	3.79±1.95*	3.80±2.21

*Values are mean ± SD., unless indicated otherwise. The unpaired student ttest was applied. Significance was calculated in comparison to QQ, QR, QR + RR, RR carriers : *p<0.05, **p<0.01, ***p<0.001 and in comparisons between QQ and RR carriers ++p<0.01, and in comparison between QQ and QR+ RR carriers ¶p<0.05*

In diabetic patients, the adjusted OR comparing the PON1 QQ variant with the PON1 QR variant was 1.37 (95% CI: 0.62-3.04). In contrast, the adjusted OR comparing the PON1 QQ and PON1 RR variants was 0.84 (95% CI: 0.22-3.25). Among hemodialysis patients, the adjusted ORs comparing the PON1 QQ variant with the PON1 QR and PON1 RR variants were 1.52 (95% CI: 0.69-3.35) and 1.97 (95 % CI: 0.63-6.21).

The observed allelic frequency distribution of PON1 showed Q allele frequencies of 86.62%, 85.46%, and 79.78%, for R allele frequencies of 13.37%, 14.53%, and 20.22% in healthy, diabetic and hemodialysis patients, respectively.

The adjusted ratio OR1 comparing the frequency of the PON1 risk allele R between heathy and diabetic subjects was 1.10 (95% CI: 0.492.45). Similarly, the OR2 comparing healthy and hemodialysis subjects was 1.64 (95% CI: 0.773.49) (Table 2).

Our result showed that, triglycerides levels were significantly higher in hemodialysis patients carrying the PON1 QQ phenotype compared with healthy QQ carriers (p<0.001). Similarly, triglyceride concentrations were significantly elevated in hemodialysis patients carrying the PON1 QR (p < 0.001) and combined PON1 QR + RR phenotypes (p<0.001) compared with healthy subjects with the corresponding phenotypes.

Higher triglyceride concentrations were also observed in diabetic subjects carrying the PON1 QQ phenotype compared with healthy QQ carriers, although the difference was not statistically significant (p = 0.12). A similar trend was observed in diabetic subjects carrying the combined PON1 QR + RR phenotypes compared with healthy QR+RR carriers (p = 0.13). In contrast, diabetic patients carrying the PON1 QR phenotype had significantly higher triglyceride levels than healthy QR carriers (p< 0.05).

Interestingly, hemodialysis exhibited significantly higher triglyceride levels than diabetic subjects across the PON1 QQ (p < 0.001), PON1 QR (p < 0.001), combined PON1 QR + RR phenotype (p<0.001).

Allelic frequency	Healthy subjects	Diabetic subjects	Hemodialysis subjects	OR1 (95%IC)	OR2 (95%IC)

Table 2 : Paraoxonase 1 allelic frequency distribution in healthy, diabetic and hemodialysis subjects

*The distribution of alleles frequencies of each polymorphism was compared between case and control subjects using χ^2 test. OR1 was calculated for diabetic versus healthy subjects, whereas OR2 was calculated for hemodialysis **versus** healthy subjects.*

The gender-specific distribution of PON1 allelic frequencies in men showed Q allele frequencies of 90.69 ± 3.13%, 90.54 ± 3.40%, and 81.54 ± 3.40% and R allele frequencies of 9.30 ± 3.13%, 9.46 ± 3.40%, and 18.46 ± 3.40% in healthy, diabetic and hemodialysis subjects, respectively (Table 3).

In women, the distribution of PON1 allelic frequencies showed Q allele frequencies of 83.72 ± 3.98%, 81.63 ± 3.91%, and 75 ± 6.24%, and R allele frequencies of 16.28 ± 3.98%, 18.37 ± 3.91%, 25 ± 6.24% respectively in healthy, diabetic, and hemodialysis subjects, respectively (Table 3).

Q	86.62±2.59%	85.46±2.69%	79.78±3%	1	1
R	13.37±2.59%	14.53±2.69%	20.22±3%	1.10(0.492.45)	1.64(0.773.49)

	Allelic frequency	Healthy subjects	Diabetic subjects	Hemodialysis subjects	OR1 (95%IC)	OR2 (95%IC)
Male	Q	90.69±3.13%	90.54±3.40%	81.54±3.40%	1	1
	R	9.30±3.13%	9.46±3.40%	18.46±3.40%	1.02(0.392.64)	2.21(0.955.13)
Female	Q	83.72±3.98%	81.63±3.91%	75±6.24%	1	1
	R	16.28±3.98%	18.37±3.91%	25±6.24%	1.16(0.562.41)	1.71(0.853.44)

Table 3 : Paraoxonase 1 allelic frequency distribution by gender in healthy, diabetic and hemodialysis subjects

The distribution of alleles frequencies of each polymorphism was compared between case and control subjects using χ^2 test. OR1 was calculated for diabetic versus healthy subjects, whereas OR2 was calculated for hemodialysis versus healthy subject.

In men, the adjusted OR comparing the PON1 R allele with the Q allele was OR1 = 1.02 (95% CI: 0.392.64) in diabetic subjects and OR2 = 2.21 (95% CI: 0.955.13) in hemodialysis subjects. In women the adjusted OR comparing the PON1 R allele with the Q allele was OR1 = 1.16 (95% CI: 0.562.41) in diabetic subjects and OR2= 1.71 (95% CI: 0.853.44) in hemodialysis subjects (Table 3).

We also investigated the allelic frequency distribution of PON1 according to age. Among subjects aged 40-60 years, the frequencies of the PON1 Q allelic were 85.71 ± 3.30%, 87.74 ± 3.18%, and 74.44 ± 4.60%, whereas the frequencies of the R allele were 14.29 ± 3.30%,

Allelic frequency	Healthy subjects	Diabetic subjects	Hemodialysis subjects	OR1 (95%IC)	OR2 (95%IC)

12.26 ± 3.18%, 25.56 ± 4.60%, in healthy, diabetic, and hemodialysis subjects, respectively (Table 4). In subject aged 40-60 years, the adjusted OR comparing the PON1 R allele with the Q allele was OR1 =0.84 (95% CI: 0.371.90) for diabetic subjects and OR2 = 2.06 (95% CI: 1-4.22) for hemodialysis subjects.

Table 4 : Paraoxonase 1 allelic frequency distribution as a function of age in healthy, diabetic and hemodialysis subjects

The distribution of allele frequencies of each polymorphism was compared between case and control subjects using χ^2 test. OR1 was calculated for diabetic versus healthy subjects. Whereas OR2 was calculated for hemodialysis versus healthy subjects.

Among subject aged 60-80 years, the frequencies of the PON1 Q allele were 83.33 ± 4.81%, 81.82 ± 4.75%, and 85.22 ± 3.78%, whereas the frequencies of the PON1 R allele were 16.67 ± 4.81%, 18.18 ± 4.75%, and 14.77 ± 3.78% in healthy, diabetic, and hemodialysis subjects, respectively (Table 4).

In subjects aged 60-80 years, the adjusted OR comparing the PON1 R allele with the Q allele was OR1 = 1.11 (95% CI: 0.532.31) for diabetic subjects and OR2=0.87 (95% CI: 0.41.86) for hemodialysis subjects.

[4060 years[	Q	85.71±3.30%	87.74±3.18%	74.44±4.60%	1	1
	R	14.29±3.30%	12.26±3.18%	25.56±4.60%	0.84(0.371.90)	2.06(14.22)
[6080 years]	Q	83.33±4.81%	81.82±4.75%	85.22±3.78%	1	1
	R	16.67±4.81%	18.18±4.75%	14.77±3.78%	1.11(0.532.31)	0.87(0.41.86)

PON1	OR1 (95%IC)	OR2 (95%IC)
Q	1	1
QR	1.37 (0.62-3.04)	1.52 (0.69-3.35)

We also investigated the adjusted OR associated with the PON1 QQ, QR and RR phenotypes according to age in diabetic and hemodialysis subjects. Among diabetic subjects aged 40-60 years, the adjusted OR comparing the QQ phenotype with the QR phenotype was OR1=1.15 (95% CI: 0.44-3.00), whereas the OR comparing the QQ phenotype with the RR phenotype was OR1 = 0.35 (95% CI: 0.03-3.50). Among diabetic subjects aged 60-80 years, the adjusted OR comparing the QQ phenotype with QR phenotype was OR1 = 2.08 (95% CI: 0.47-9.29), whereas the OR comparing QQ phenotype with the RR phenotype was OR2=1.56 (95% CI: 0.24-10.19).

RR	0.84 (0.22-3.25)	1.97 (0.63-6.21)

Table 5 : Adjusted odd ratio in diabetic and hemodialysis subjects associated with the risk of cardiovascular diseases

PON1	OR1 (95%IC)	OR2 (95%IC)

OR1 was calculated for diabetic versus healthy subjects, whereas OR2 was calculated for hemodialysis versus healthy subjects.

Among hemodialysis subjects aged 40-60 years, the adjusted OR comparing the PON1 QQ phenotype with the QR phenotype was OR2=1.33 (95% CI: 0.48-3.69), whereas the adjusted OR comparing the QQ phenotype with the RR phenotype was OR2= 3.46 (95% CI: 0.83-14.49) for RR. Among hemodialysis subjects aged 60-80 years, the adjusted OR comparing the PON1 QQ phenotype with the QR phenotype was OR2 = 2.27 (95% CI: 0.56-9.27), whereas the adjusted OR comparing QQ phenotype with the RR phenotype was OR2= 0.76 (95% CI: 0.10-5.76) (Table 5).

Table 6 : Adjusted odd ratio in diabetic and hemodialysis subjects and the associated risk of PON1 Q192R polymorphism

	Q	1	1
[4060 years[	QR	1.15 (0.44-3.00)	1.33 (0.48-3.69)
	RR	0.35 (0.03-3.5)	3.46 (0.83-14.49)
[6080 years]	Q	1	1
	QR	2.08 (0.47-9.29)	2.27 (0.56-9.27)
	RR	1.56 (0.24-10.19)	0.76 (0.10-5.76)

OR represents the adjusted odds ratio. OR1 was calculated for diabetic versus healthy subjects, whereas OR2 was calculated for hemodialysis versus healthy subjects.

Discussion

Many studies support the role of oxidative stress in the pathogenesis of diabetes and chronic renal failure [16, 17, 18]. The main findings of this study were that, the PON1 Q192 R variant was more frequent in diabetic and hemodialysis subjects. Factors affecting serum PON1 activity include type 1 and 2 diabetes mellitus, chronic renal disease, familial hypercholesterolemia, and inflammatory disorder such as rheumatoid arthritis and hemodialysis [19-22].

In our study, we observed an increase of Vit.E/TC ratio in PON1 QQ by comparison to RR , indicating reduced lipid peroxidation and lower oxidative stress in subject with PON1 QQ. It is known that, the PON1 QQ inhibits the initiation and propagation of lipid peroxidation [23-25]. Vitamin E is a chain breaking antioxidant stopping the propagation of lipid peroxidation [26]. It also suggested that PON1 polymorphism may affect the ability of Vit.E to impede the development of atherosclerosis and to prevent inflammation.

We observed an increase of Vit E /CT ratio in PON1 QQ carriers by comparison to PON1 RR carriers in diabetics and hemodialysis indicating changes in lipid profile in these subjects. Aviram et al. reported that, PON1 inhibits efficiently the production of lipid peroxides at 61 % and aldehyde compounds at 58 % [23-25]. PON1 also inhibits LDL oxidation efficiently if it presents in initiation of lipid peroxidation step. But the PON1 RR inhibits production of lipid peroxidation at 46 % and aldehyde compounds in 38% [23-25].

Published data on the association between PON1 polymorphisms and coronary heart disease have yielded controversial results [27]. Study from Bub et al. indicates that, PON 1 Q192R polymorphism is associated with reduced lipid peroxidation in R-allele-carriers but not in QQ homozygous elderly subjects on a tomato-rich diet [27].

The relationship between the two human PON1 amino acid variants, the Leu55Met and the Gln192Arg polymorphism, and the risk of cardiovascular disease is also documented in this study. The main purpose is to investigate the link between the PON1 allele frequency distribution, adjusted odds ratio and the risk of cardiovascular diseases development in a Moroccan population.

Our result showed a high risk of cardiovascular disease in QR carriers vs QQ carriers in diabetic [OR1= 1.37; 95% CI: 0.62-3.04] and hemodialysis subjects [OR2=1.52; 95% CI: 0.69-3.35].

The risk of cardiovascular diseases in QR and RR diabetic and hemodialysis subjects is due to Gln192Arg polymorphism of PON1. The Gln192Arg polymorphism of PON1 indicates changes from glutamine (the Q variant) to arginine (the R variant) at position 192 of the amino acid sequence [8,9]. These changes may affect its hydrolytic activity [23, 24]. Arginine is a conditionally essential amino acid serving as a substrate for protein synthesis, L-arginine is the pre- cursor for nitric oxide (NO), is responsible for free radical production [[9, 28]. These results are in line with other studies that investigated PON1 polymorphism related to cardiovascular diseases risk [19, 29, 30].

We also observed that, the PON1 192Q allele frequency (86.62%; 85.46% and 79.78%) is higher than that of PON1 192R allele frequency (13.37%; 14.53% and 20.22%) respectively in healthy, diabetic and hemodialysis subjects. Van Den Berg et al. observes comparable R-allele frequencies for subjects with normal Glucose Tolerance 32% and Newly diagnosed Type 2 diabetes 25% [31]. This study confirms that, the PON1 192 R allele is responsible for cardiovascular disease in diabetic and hemodialysis patients.

In the present study, we have shown that, PON1 192 R allele provides lowest protection against oxidative stress in diabetic and hemodialysis patients. As a function of age, we note a high risk of cardiovascular diseases in hemodialysis [OR2=2.06; 95% CI: 1-4.22] and diabetic subjects [OR1=1.11; 95% CI: 0.53-2.21] when comparing allelic frequencies homozygosity for QQ variant and RR variant. These results suggest that, oxidative stress damage is higher in our subjects.

Paraoxonase 1 Arg 192 Gln allelic frequency distribution showed a high frequency of the R allele in female diabetic. Our diabetic women were obese and hypertensive. Hypertension

affects the PON1 activity and also increases the susceptibility to atherosclerosis [32]. It also compromises the capacity of their HDL to prevent the accumulation of lipid peroxide on human LDL [33]. Lawlor et al. study indicated that, there was a high risk of cardiovascular diseases among the findings from the British Women's Heart and Health cohort study and a meta-analysis over 60 years [34]. PON1 allelic frequency distribution is elevated in male and female hemodialysis patients as a result of dialysis process. Dialysis process produces free radicals responsible for oxidative damage in these subjects [35, 36]. Hemodialysis alters also lipid profile, total antioxidant capacity, vitamin A, E and C concentration in humans and also increase cardiovascular diseases development [37]. To our knowledge, few studies provide data of the PON1 Q192R polymorphism related to cardiovascular diseases in hemodialysis patients.

Our study has shown that, diabetic subjects and hemodialysis patients carrying RR and QR had high triglycerides level when compared to healthy control carrying QQ. These results are in line with others studies [38, 39]. Jarvik et al. reported that PON1 is a better predictor of vascular diseases than be the PON1-192 or PON1-55 [38]. This study showed that the R allele alters the reactivity of the paraoxonase [38]. Our result which is in agreement with other studies suggested that PON1 activity can be used as a cardiovascular disease prediction marker in healthy, diabetic and hemodialysis patients [38, 39]. Our study confirms that, PON1 polymorphisms affects the lipid profile, particularly it showed that the R allelic frequency of PON1 disturbs serum triglycerides distribution in lipoproteins. Compared with hemodialysis patients, diabetic subjects had better lipid profile (lower triglyceride) because they reported a higher use of lipid medication. Deakin et al. reported that Statins modulates the expression of the PON1 gene and increase serum Paraoxonase [40]. A logical explanation appears to be the higher frequency of the R allele in our hemodialysis patients. These findings point at less protection against oxidation and higher risk of cardiovascular diseases at the beginning of chronic renal disease [40, 41]. A plausible explanation can be the high level of triglycerides in Hemodialysis subjects which alter the composition of HDL, VLDL, LDL cholesterol, and finally influence the PON1 binding and its activity [41].

In our study, the low risk of CVD observed in Morocco is due to Mediterranean diet. Mediterranean diet generically describes an eating pattern. In Morocco, the diet is rich in argan oil, fruit and vegetable. The benefits of this diet is its content in antioxidant particularly Vitamin E. The Mediterranean diet lowers the risk of heart disease and early death.

In conclusion, this study investigates the relationship between PON1 phenotype distribution and the risk of cardiovascular disease development in healthy, diabetic and hemodialysis patients. Our findings suggest a slight increase in cardiovascular risk, particularly among carriers of the R allele.

References

[1] Foley R.N., Parfrey P.S. and Sarnak M.J.. Epidemiology of cardiovascular diseases in chronic renal disease. J Am Soc Nephrol 9 (1998) 16-23.

[2] Gbandjaba N.Y., Hassar M., Saile R., Berrougui H., Taki H., Lebrazi H., Ghalim N., Khalil A. Paraoxonase activity in healthy, diabetic and hemodialysis patients. Clin Biochem. 45 (2012) 470-474.

[3] Murray J.L., Lopez A.D . Global mortality, disability, and the contribution of risk factors : Global Burden of Disease Study. Lancet 349 (1997) 1436-1442.

[4] Ross R. The pathogenesis of atherosclerosis : a perpective for the 1990s. Nature 362 (1993) 801-809

[5] Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241.

[6] Mackness B., Durrington P.N., Mackness M.I. Human serum paraoxonase. Gen Pharmacol. 31 (1998) 329-336.

[7] Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891.

[8] Smolen A., Eckerson H.W., Gan K.N., Hailat N., La Du B.N. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase. Drug Metab Dispos 19 (1991) 107-112.

[9] Mogarekar M.R., Chawhan S.S. The determination of Q192R polymorphism of paraoxonase 1 by using non toxic substrate p-nitrophenylacetate. Indian J Hum Genet 19 (2013) 71-77

[10] Mahrooz A., Alizadeh A., Gohari G. The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke : the role of activity-determined PON1 192Q/R phenotypes. J Neurol Sci 338 (2014) 197-2002.

[11] Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., Furlong C.E.. The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism. Chem Biol Interact 119-120 (1999) 429-438.

[12] Lahrach H., Essiarab F., Timinouni M., Hatim B., El Khayat S., Er-Rachdi L., Jarir J., Kettani A., Ghalim N., Taki H., Lebrazi H., Ramdani B., Saïle R.. Association of apolipoprotein E gene polymorphism with end-stage renal disease and hyperlipidemia in patients on long-term hemodialysis. Ren Fail. 26 (2014) 1-6.

[13] Ferretti G., Bacchetti T., Busni D., Rabini R.A., Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation : a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab. 89 (2004) 2957-2962.

[14] Mackness B., Durrington P.N., Mackness M.I. Human serum paraoxonase. Gen Pharmacol. 31 (1998) 329-336.

[15] Deakin S.P., James R.W. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci. 107 (2004) 435-447.

[16] Cerit N., Onuk A. A., Ellidag H.Y., Eren E., Bulbuler N., Yilmaz N. Arylesterase and oxidative stress in opering room personnel. Adv Clin Exp Med. 23 (2014) 49-55

[17] Bozkürk M.B, Günay E., Ogan N., Candemir İ., Eker U., Öztürk A. Serum paraoxonase-1 as a marker of oxidative stress and pulmonary dysfunction in sarcoidosis: association with disease activity and prognostic potential. Front Immunol. 16 (2026) 1731991. doi: 10.3389/fimmu.2025.1731991. eCollection 2025.

[18] Gašperšič R., Taler-Verčič A., Petrič B., Goličnik M., Bavec A. Total esterase and paraoxonase activity in human saliva of periodontitis patients and healthy individuals; a pilot study. Chem Biol Interact. 423 (2026) :111836. doi: 10.1016/j.cbi.2025.111836.

[19] Delibaş E.A.Ö, Köse K., Yazici C., Tokgöz B. Oxidative Stress-Related HDL Dysfunction in Hemodialysis: The Clinical Utility of MPO/PON1 and MPO/HDL-C Ratios in Cardiovascular Risk Assessment. Ther Apher Dial. 30 (2026) 78-84. doi: 10.1111/1744-9987.70094. Epub 2025 Nov 9.

[20] Parfentyeva E., Saha S., Hjellset V. T., Kopprasch S., Schwarz P. E. Assessment of small C-Fiber status for screening of oxidative stress in patients at high risk of Diabetes. Horm Metab Res 46 (2014) 360-364

[21] Bernal-Hernandez Y.Y., Medina-Diaz I.M., Barron-Vivanco B.S.. Robledo-Marenco MdeL, Giron-Perez M.I., Perez-Herrera N.E., Quintanilla-Vega B., Cerda-Florez R., Rojas-Garcia A.E. Paraoxonase 1 and its relationship with pesticide biomarkers indigenous mexican farmworkers. J Occup Environ Med. 56 (2014) 291-290.

[22] Paragh G., Törocsik D., Seres I, Harangi M., Illyés L., Balogh Z., Kovács P. Effect of short term treatment with simvastatin and atorvastatin on lipid and paraoxonase activity in patients with hyperlipoproteinaemia. Curr Med Res Opin. 20 (2004) 1321-1327.

[23] Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du. B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. European journal of clinical investigation. (1998a) 1581-1590.

[24] Aviram M., Rosenblat M., Billecke S., Eurogul J., . Sorenson R, Bisgaier C.L., Newton R.S., La Du B.N. Human serum paraoxonase (PON1) is inactivated by oxidized low density

lipoprotein and preserved by antioxidants. Free Radical Biology and Medicine. 26 (1999) 892-904

[25] Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities : selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18 (1998b) 1617-1624.

[26] Halliwell B. The chemistry of free radicals. Toxicology and industrial health. 9 (1993) 1-21.

[27] Bub A., Barth S., Watzl B., Briviba K., Herbert B.M., Lührmann P.M., Neuhäuser-Berthold M., Rechkemmer G. Paraoxonase 1 Q192R (PON1-192) polymorphism is associated with reduced lipid peroxidation in R-allele-carrier but not in QQ homozygous elderly subjects on a tomato-rich diet. J Nutr. 134 (2004) 1081-3.

[28] Diepeveen S.H., Verhoeven G.H., Van Der Palen J., Dikkeschei B.L., Van Tits L.J., Kolsters G., Offerman J.J., Bilo H.J., Stalenhoef A.F. Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract 98 (2004) 3-7.

[29] Watzinger N., Schmidt H., Schumacher M., Schmidt R., Eber B., Fruhwald F.M., Zweiker R., Kostner G.M., Klein W.. Human Paraoxonase1 Gene Polymorphisms and the Risk of Coronary Heart Disease: A Community-Based Study. Cardiology (2002) 98 (3): 116–122.

[30] Newton R.S., La Du B.N. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biology and Medicine. 26 (1999) 892-904.

[31] Van Den Berg S.W., Jansen E.H., Kruijshoop M., Beekhof P.K., Blaak E., Van Der Kallen C.J., Van Greevenbroek M.M., Feskens E. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabetic medicine. 25 (2008) 186-193.

[32] Diyane K., El Ansari N., El Mghari G., Anzid K., Cherkaoui M. Characteristics of the association type 2 diabetes and hypertension in the elderly aged 65 and over. Pan Afr Med J. 14 (2013) 100.

[33] Reaven P. D., Napoli C., Merat S., Witztumc J.L. Lipoprotein modification and atherosclerosis in aging. Exp Gerontol 34 (2000) 527-537.

[34] Lawlor D. A., Day I. N. M. , Gaunt T. R., Hinks L. J, Timpson N., Ebrahim S., Smith G. D.. The association of the paraoxonase (PON1) Q192R polymorphism with depression in older women: findings from the British Women's Heart and Health Study. Journal of epidemiology and community health. 61 (2007) 85-7.

[35] Daschner M., Lenhartz H., Botticher D. Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 50 (1996) 1262-1268.

[36] Lacson E. Jr. and Lazarus J.M. Dialyzer best practice : single use or reuse ?. Semin Dial 19 (2006) 120-128.

[37] El Muhtaseb M.S., Talwar D., Duncan A., O'reilly D.S., McKee R.F., Anderson J.H., Foulis A., Finlay I.G. Free radical activity and lipid soluble anti-oxidant vitamin status in patients with long-term ileal pouch-anal anastomosis. Colorectal Dis 11 (2008) 67-72.

[38] Jarvik J.P., Rosek L.S., Brophy B.H., Hatsukami T.S., Richter R.J., Schellenberg G.D., Furlong C.E. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1(55) genotype. Atherosclerosis, thrombosis, and vascular biology. 20 (2000) 2441-2447

[39] Gugliucci A. Activation of paraoxonase 1 is associated with HDL remodelling ex vivo. Clin Chem Acta. 429 (2014) 38-45

[40] Deaking S., Leview I., Brulhurt-Meynet MC, James RW. Paraoxonase 1 promoter and serum paraoxonase : a predominante role for polymorphic-107 implicating the Sp1 factor. Biochem J 372 (2003) 643-649

[41] Senti M., Tomás M., Marrugat J., Elosua R. Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs. Atherosclerosis, Thrombosis and Vascular biology. 21 (2001) 415-420.